---
document_datetime: 2025-08-04 16:43:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/docetaxel-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: docetaxel-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6056976
conversion_datetime: 2025-12-20 18:53:39.146741
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Docetaxel Kabi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 04/08/2025                          |                                             | SmPC and PL                      | To update the PI with information on polysorbate 80 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282406                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To update the PI with information on polysorbate 80 based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. Additionally, the MAH took the opportunity to implement editorial changes, including: - the removal of a line of EN text in the IT PI, - the correction of an error in the Marketing Authorization Number in the HU PI, - corrections of grammatical and typographic errors in the CZ PL, - and the alignment of text in the CZ PL for the different strengths with the PL for 20 mg/1 ml, which has undergone linguistic review.   |            |     | based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000279038 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Minor change of an analytical procedure for an in-process control - Accepted                                                                                                                                                                                                                                                                                                            | 09/07/2025 | N/A |                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000281056   | This was an application for a group of variations.   | 26/06/2025   | N/A   |
|-----------------------------------------|------------------------------------------------------|--------------|-------|